Cyrus Poonawalla Group

"SAROSH BHAVAN", 16-B/1, DR. AMBEDKAR ROAD, PUNE - 411 001, INDIA. ■TEL.: +91-20-26137221-5 ■ FAX: +91-20-26133228 CIN U80903PN1984PTC032945

22nd December, 2020

To Ravinder Heights Limited Ground Floor, PDS Block, Ambala-Chandigarh Highway Lalru - 140501

Dear Sir,

We would like to inform you, as required under the provisions of Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulation, 2011, in respect of our holding in your Company's shares listed over the Stock Exchange.

Please find enclosed the said declaration made in our capacity as 'Acquirer' and on behalf of other 'Acquirer' Companies, in their capacity as 'Person Acting in Concert', as required under the aforesaid Regulation.

Kindly acknowledge the receipt of the same.

Thanking you,

Yours faithfully,

For Serum Institute of India Private Limited

Authorised Signatory

Copy to:

The Company Secretary
Ravinder Heights Limited
7th Floor, DCM Building, 16,
Barakhamba Road,
New Delhi 110001

REGD. OFFICE : 212/2 Off Soli Poonawalla Road, Hadapsar, Pune - 411 028. INDIA Tel. : +91-20-26993900 / 04 ■ Fax : +91-20-26993904 / 3921 ■ www.seruminstitute.com

Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	RAVINDER HEIGHTS LIMITED		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Acquirer: 1. Serum Institute of India Private Limited PAC's: 2. Chakan Investment Private Limited 3. Corpint Investments Private Limited 4. Fortune Intercontinental Private Limited 5. Mr. Adar C Poonawalla		
Whether the acquirer belongs to Promoter/Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	NSE, BSE		
Details of the acquisition / disposal as follows	Number	% w.r.t.total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of: a) Shares carrying voting rights b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	- -	-	-
 c) Voting rights (VR) otherwise than by shares d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) 	-	-	-
e) Total (a+b+c+d)	-	-	-
Details of acquisition/sale			
a) Shares carrying voting rights acquired/sold	85,10,591	13.89%	13.89%
 b) VRs acquired /sold otherwise than by shares c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold 	-	- - -	
d) Shares encumbered / invoked/released by the acquirer e) Total (a+b+c+/-d)	85,10,591	13.89%	13.89%

After the acquisition/sale, holding of:				
a) Shares carrying voting rights	85,10,591	13.89%	13.89%	
b) Shares encumbered with the acquirer	-	-	-	
c) VRs otherwise than by shares				
d) Warrants/convertible securities/any other instrument	-	-	-	
that entitles the acquirer to receive shares carrying				
voting rights in the TC (specify holding in each	-	-	-	
category) after acquisition				
e) Total (a+b+c+d)	85,10,591	13.89%	13.89%	
Mode of acquisition / sale (e.g. open market / off-market /	Allotted pursuant to Scheme of Arrangement between Panacea Biotec Limited and Ravinder			
public issue / rights issue / preferential allotment / inter-se				
transfer etc).	Heights Limit	Heights Limited and their respective Shareholders		
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	6th October, 2020			
Equity share capital / total voting capital of the TC before the said acquisition / sale	6,12,50,746			
Equity share capital/ total voting capital of the TC after the said acquisition / sale	6,12,50,746	6,12,50,746		
Total diluted share/voting capital of the TC after the said acquisition	6,12,50,746			

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

For Serum Institute of India Private Limited

Authorised Signatory

Place: Pune

Date: 22nd December, 2020